RT Journal Article
SR Electronic
T1 Controlling COVID-19 via test-trace-quarantine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.15.20154765
DO 10.1101/2020.07.15.20154765
A1 Kerr, Cliff C.
A1 Mistry, Dina
A1 Stuart, Robyn M.
A1 Rosenfeld, Katherine
A1 Hart, Gregory R.
A1 Núñez, Rafael C.
A1 Selvaraj, Prashanth
A1 Cohen, Jamie A.
A1 Abeysuriya, Romesh G.
A1 George, Lauren
A1 Hagedorn, Brittany
A1 Jastrzębski, Michał
A1 Fagalde, Meaghan
A1 Duchin, Jeffrey
A1 Famulare, Michael
A1 Klein, Daniel J.
YR 2020
UL http://medrxiv.org/content/early/2020/10/03/2020.07.15.20154765.abstract
AB Initial COVID-19 containment in the United States focused on limiting mobility, including school and workplace closures. However, these interventions have had enormous societal and economic costs. Here we explore the feasibility of an alternative control strategy, test-trace-quarantine: routine testing of primarily symptomatic individuals, tracing and testing their known contacts, and placing their contacts in quarantine. We performed this analysis using Covasim, an open-source agent-based model, which was calibrated to detailed demographic, mobility, and epidemiological data for the Seattle region from January through May. With current levels of mask use and schools remaining closed, we predict that high but achievable levels of testing and tracing are sufficient to maintain epidemic control even under a return to full workplace and community mobility. The easing of mobility restrictions in June and subsequent scale-up of testing and tracing programs provided real-world validation of our predictions. Although we show that test-trace-quarantine can control the epidemic in both theory and practice, its success is contingent on high testing and tracing rates, high quarantine compliance, relatively short testing and tracing delays, and moderate to high mask use. Thus, in order to control transmission with a return to high mobility, strong performance in all aspects of the program is required.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the Bill and Melinda Gates Foundation. Institutional support, including high-performance computing resources and library access, was provided by the Burnet Institute and the University of Sydney School of Physics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approval required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Covasim model code is fully open source and available via GitHub. Most data are available from the King County Data Dashboard; data not publicly released are available upon request with permission from Public Health Seattle & King County. Analysis scripts are available from the authors upon request. https://github.com/institutefordiseasemodeling/covasim